annual CFF:
$281.63M-$276.71M(-49.56%)Summary
- As of today (June 29, 2025), IBRX annual cash flow from financing activities is $281.63 million, with the most recent change of -$276.71 million (-49.56%) on December 31, 2024.
- During the last 3 years, IBRX annual CFF has fallen by -$223.81 million (-44.28%).
- IBRX annual CFF is now -49.56% below its all-time high of $558.34 million, reached on December 31, 2023.
Performance
IBRX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$982.00K-$107.91M(-100.92%)Summary
- As of today (June 29, 2025), IBRX quarterly cash flow from financing activities is -$982.00 thousand, with the most recent change of -$107.91 million (-100.92%) on March 31, 2025.
- Over the past year, IBRX quarterly CFF has dropped by -$11.21 million (-109.60%).
- IBRX quarterly CFF is now -100.30% below its all-time high of $325.95 million, reached on December 31, 2021.
Performance
IBRX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$270.42M-$11.21M(-3.98%)Summary
- As of today (June 29, 2025), IBRX TTM cash flow from financing activities is $270.42 million, with the most recent change of -$11.21 million (-3.98%) on March 31, 2025.
- Over the past year, IBRX TTM CFF has dropped by -$221.25 million (-45.00%).
- IBRX TTM CFF is now -54.72% below its all-time high of $597.16 million, reached on June 30, 2024.
Performance
IBRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
IBRX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -49.6% | -109.6% | -45.0% |
| 3 y3 years | -44.3% | -229.5% | -42.0% |
| 5 y5 years | +146.4% | -698.4% | +10000.0% |
IBRX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -49.6% | +20.6% | -100.4% | at low | -54.7% | +15.8% |
| 5 y | 5-year | -49.6% | +146.4% | -100.3% | at low | -54.7% | >+9999.0% |
| alltime | all time | -49.6% | +146.4% | -100.3% | at low | -54.7% | >+9999.0% |
IBRX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$982.00K(-100.9%) | $270.42M(-4.0%) |
| Dec 2024 | $281.63M(-49.6%) | $106.93M(+586.2%) | $281.63M(-24.9%) |
| Sep 2024 | - | $15.58M(-89.5%) | $375.24M(-37.2%) |
| Jun 2024 | - | $148.89M(+1356.2%) | $597.16M(+21.5%) |
| Mar 2024 | - | $10.22M(-94.9%) | $491.68M(-11.9%) |
| Dec 2023 | $558.34M(+139.0%) | $200.54M(-15.6%) | $558.34M(+19.4%) |
| Sep 2023 | - | $237.50M(+447.1%) | $467.74M(+32.0%) |
| Jun 2023 | - | $43.41M(-43.5%) | $354.23M(+14.0%) |
| Mar 2023 | - | $76.89M(-30.1%) | $310.80M(+33.0%) |
| Dec 2022 | $233.61M | $109.94M(-11.3%) | $233.61M(-48.0%) |
| Sep 2022 | - | $123.99M(<-9900.0%) | $449.63M(+22.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$15.00K(-95.0%) | $368.30M(-21.1%) |
| Mar 2022 | - | -$298.00K(-100.1%) | $466.65M(-7.7%) |
| Dec 2021 | $505.44M(+235.5%) | $325.95M(+664.1%) | $505.44M(+181.2%) |
| Sep 2021 | - | $42.66M(-56.6%) | $179.73M(-10.3%) |
| Jun 2021 | - | $98.34M(+155.4%) | $200.29M(+5.8%) |
| Mar 2021 | - | $38.50M(>+9900.0%) | $189.29M(+25.6%) |
| Dec 2020 | $150.68M(+31.8%) | $241.00K(-99.6%) | $150.68M(+0.2%) |
| Sep 2020 | - | $63.22M(-27.6%) | $150.43M(+72.5%) |
| Jun 2020 | - | $87.34M(<-9900.0%) | $87.22M(<-9900.0%) |
| Mar 2020 | - | -$123.00K | -$123.00K |
| Dec 2019 | $114.28M | - | - |
FAQ
- What is ImmunityBio annual cash flow from financing activities?
- What is the all time high annual CFF for ImmunityBio?
- What is ImmunityBio annual CFF year-on-year change?
- What is ImmunityBio quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ImmunityBio?
- What is ImmunityBio quarterly CFF year-on-year change?
- What is ImmunityBio TTM cash flow from financing activities?
- What is the all time high TTM CFF for ImmunityBio?
- What is ImmunityBio TTM CFF year-on-year change?
What is ImmunityBio annual cash flow from financing activities?
The current annual CFF of IBRX is $281.63M
What is the all time high annual CFF for ImmunityBio?
ImmunityBio all-time high annual cash flow from financing activities is $558.34M
What is ImmunityBio annual CFF year-on-year change?
Over the past year, IBRX annual cash flow from financing activities has changed by -$276.71M (-49.56%)
What is ImmunityBio quarterly cash flow from financing activities?
The current quarterly CFF of IBRX is -$982.00K
What is the all time high quarterly CFF for ImmunityBio?
ImmunityBio all-time high quarterly cash flow from financing activities is $325.95M
What is ImmunityBio quarterly CFF year-on-year change?
Over the past year, IBRX quarterly cash flow from financing activities has changed by -$11.21M (-109.60%)
What is ImmunityBio TTM cash flow from financing activities?
The current TTM CFF of IBRX is $270.42M
What is the all time high TTM CFF for ImmunityBio?
ImmunityBio all-time high TTM cash flow from financing activities is $597.16M
What is ImmunityBio TTM CFF year-on-year change?
Over the past year, IBRX TTM cash flow from financing activities has changed by -$221.25M (-45.00%)